Spyre Therapeutics CFO Burrows Scott L exercised Options for 7,500 shares at $14.50 per share on 2026-09-01. For investors, the transactions changed his reported holdings to 79,762 shares after sales, while derivative securities stood at 337,357 after the exercise.

Key Highlights

  • Burrows Scott L sold 25,732 Spyre Therapeutics shares at prices ranging from $86.25 to $89.35 per share.
  • His reported share ownership stood at 79,762 after the sales.
  • His derivative securities ownership reached 337,357 after the option exercise.

Spyre Therapeutics, Inc. (NASDAQ: SYRE) CFO Burrows Scott L exercised options for 7,500 shares at $14.50 per share on 1 September 2026.

Option Exercise and Share Sales

The option exercise covered 7,500 shares at $14.50 per share. Burrows Scott L also sold a total of 25,732 Spyre Therapeutics shares in separate transactions conducted between 1 September 2026 and 2 September 2026. The sale prices ranged from $86.25 to $89.35 per share. After those sales, his reported ownership of Spyre Therapeutics common stock was 79,762 shares. The exercise and sales affected separate ownership categories. The records identify Burrows Scott L as Spyre Therapeutics’ chief financial officer.

Reported Holdings After the Transactions

The transactions leave two reported ownership figures for Spyre Therapeutics common stock, reflecting holdings before and after the sales activity. Burrows Scott L’s reported common-stock position was 105,494 shares after the option exercise and 79,762 shares after the sales. His derivative securities position after the exercise was 337,357.